PLANO, Texas–(BUSINESS WIRE)– #CardiovascularResearch–Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced that clinical data from its Phase 1 study evaluating STM-01 in patients with heart failure with preserved ejection fraction (HFpEF) will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting.STM-01 is an investigational biologic therapy derived from neonatal cardiac progenito